SynBio Coalition Applauds Senate Passage of U.S. Innovation and Competition Act



WASHINGTON, June 9, 2021 / PRNewswire / – Today, the SynBio Coalition, a non-partisan group of leaders in the synthetic biology industry, yesterday welcomed the bipartisan passage of the U.S. Innovation and Competition Act (USICA) by the Senate. The USICA, which includes key provisions of the Endless Frontier Act, will strengthen US competitiveness and innovation in biotechnology and synthetic biology. It supports research, education, workforce development and other measures to coordinate scientific development and encourage the growth of a new manufacturing industry.

USICA reaffirms the importance of synthetic biology in the face of the many challenges facing the country. Notably, synthetic biology and biosafety efforts have been critical to the response to the COVID-19 pandemic, demonstrating the enormous promise of biological solutions.

This landmark legislation encompasses solutions and supports strong scientific research and economic development efforts needed to realize the powerful potential of synthetic biology. It includes strong support for STEM education and workforce development the creation of a new division within the National Science Foundation, the Directorate of Technology and Innovation; and the formation of a national bioengineering research and development initiative. Together, these and other measures will contribute to the development of the US bioeconomy, which is essential for the future of biosecurity and US economic growth. A recent report indicated that over the next decades, a visible pipeline of biological applications could create approximately $ 2 at 4 trillion dollars direct annual economic impact on a global scale.

“Yesterday’s passage represents an important inflection point for the entire synthetic biology industry, which is poised to be the main engine of economic growth and employment over the next century. “, said Christina smolke, CEO of Anthéia. “We are delighted to see bipartisan support for synthetic biology and we are committed to working with the government to harness its incredible potential.”

“Consumer demand, technological expertise and government support are a powerful trio in stimulating the continued growth of America’s bioeconomy,” said Christophe Schilling, CEO of Genomatica. “Policies and investments in synbio innovation and the growth of bio-based manufacturing are crucial support in a wholesale transition to sustainable materials, making better products with a better environmental profile to make our world a better place. ”

“As we were leaving our graduate studies at MIT In building a horizontal platform for cell programming at Ginkgo, my co-founders and I saw the transformative power of government investment in scientific innovation and coordination, ”said Jason kelly, CEO of Ginkgo Bioworks. “Our generation has an incredible opportunity to harness biology for the sustainability, health and well-being of our communities and partners around the world. Legislation like this will help us realize that future. . ”

The SynBio Coalition remains committed to working with the federal government to develop this innovative sector and create well-paying jobs in the United States, and looks forward to working with Congress and the Biden administration on these critical issues.


Founded by three of the leading synthetic biology companies, the SynBio Coalition is a non-partisan group of business leaders and stakeholders dedicated to advancing synthetic biology as a driver of technological innovation and economic growth. . The SynBio Coalition aims to make the United States home to the world’s safest and most technologically advanced bioproduction industry.

SOURCE SynBio Coalition


Leave A Reply

Your email address will not be published.